3月 2026
- 首頁
- Elixir Medical
3月 2026Elixir Medical的市場佔有率分析
A significant innovation in technologies of the treatment of CAD, DynamX is a significant breakthrough in implant design in the past 30 years.
Elixir Medical(包含公司地區)
查看更多網站流量與參與度資訊- elixirmedical.com
Elixir Medical截至 3月 2026 的總收入為 15M - 25M
Elixir Medical 熱門網域產生的總收入
Elixir Medical 熱門網域 3 年內的總收入
Elixir Medical 熱門網域的總收入
Elixir Medical的熱門網域總造訪量
了解Elixir Medical市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Elixir Medical的熱門網域平均造訪時長
分析Elixir Medical參與度指標。
過去 3 個月平均造訪時長
子公司細目
Elixir Medical的熱門網域平均頁面瀏覽量
了解Elixir Medical如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Elixir Medical
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Elixir Medical Corporation launched LithiX HC IVL system on Oct 6th '25.Elixir Medical recently announced the full market release of its LithiX HC IVL system, which received European CE Mark approval in April 2025.
11月 6, 2025閱讀更多
新聞Elixir Medical Corporation attended event Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 on Nov 7th '25.MILPITAS, Calif. - November 7, 2025 - Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, announced results from the MY-IVL Study at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco.
10月 24, 2025閱讀更多
新聞Elixir Medical Corporation attended event TCT 2025 on Oct 3rd '25.October 3, 2025 - Elixir Medical announced the full market release of its LithiX Hertz Contact (HC) intravascular lithotripsy (IVL) system, as well as commercial milestones and an upcoming presentation on the device at TCT 2025, the Transcatheter Cardiovascular Therapeutics conference.
10月 3, 2025閱讀更多
查看所有Elixir Medical信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
